ReviewFrontiers in psychiatry2019
Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder.
Review in Frontiers in psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Autophagy Modulation by Antidepressants: Mechanisms and Implications.Neurochemical research · 2025Review
- Delving into the Perception, Use, and Context of Duloxetine in Clinical Practice: An Analysis Based on the Experience of Healthcare Professionals.Brain sciences · 2025Article
- Genome-wide association study -Driven drug repositioning for the treatment of insomnia.Journal, genetic engineering & biotechnology · 2025Article
- Article
- Neurobiochemical Disturbances in Psychosis and their Implications for Therapeutic Intervention.Current topics in medicinal chemistry · 2024Review
- Daily intake of 30 mg duloxetine is effective in decreasing premature ejaculation severity: a prospective randomized placebo-controlled cross over clinical trial.Basic and clinical andrology · 2023Article
- Review
- Congenital aniridia beyond black eyes: From phenotype and novel genetic mechanisms to innovative therapeutic approaches.Progress in retinal and eye research · 2023Review
- High-content imaging of human hepatic spheroids for researching the mechanism of duloxetine-induced hepatotoxicity.Cell death & disease · 2022Article
- The Potential Antidepressant Action of Duloxetine Co-Administered with the TAAR1 Receptor Agonist SEP-363856 in Mice.Molecules (Basel, Switzerland) · 2022Article
- Neuroendocrine Stress Axis-Dependence of Duloxetine Analgesia (Anti-Hyperalgesia) in Chemotherapy-Induced Peripheral Neuropathy.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2022Article
- Current Clinical Psychopharmacology in Borderline Personality Disorder.Current neuropharmacology · 2021Review
- A Real-World, Prospective, Multicenter, Single-Arm Observational Study of Duloxetine in Patients With Major Depressive Disorder or Generalized Anxiety Disorder.Frontiers in psychiatry · 2021Article
- Antidepressant Drugs Effects on Blood Pressure.Frontiers in cardiovascular medicine · 2021Review
- Associations Among Monoamine Neurotransmitter Pathways, Personality Traits, and Major Depressive Disorder.Frontiers in psychiatry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.